Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development
Epalinges, September 19, 2016
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today the continuation of the collaboration with the Texas Biomedical Research Institute related to the Mymetics' HIV vaccine candidate.
|Media Name||Media Type||Description||Download|
|160919_ Mymetics Texas Biomedical||Download|